Novo Nordisk Receives FDA Approval for Sogroya® in Children with Turner Syndrome
The US Food and Drug Administration (FDA) has approved Novo Nordisk's once-weekly growth hormone injection, Sogroya® (somapacitan-beco), for children aged 2.5 years and older with growth failure associated with Turner Syndrome.